Geneva, 1 October 2018
By: Andreas Sandgren, ReAct – Action on Antibiotic Resistance, on behalf of Stichting Health Action International
15:30-17:00 The discussion on Annex 1 and 2 focuses on Annex 1 and 2, including Selected Financing Mechanisms and the current R&D Landscape, and and overall discussion of the way forward with the work on the framework.
Chair, on behalf of Health Action International, ReAct – Action on Antibiotic Resistance is grateful for the opportunity to take the floor again.
- R&D financing cannot be seen a separate issue from securing affordable access nor stewardship of end products. The choices that governments make on R&D financing models will greatly impact our efforts to secure affordable access to end products, as well as our ability to preserve their effectiveness through stewardship efforts.
- Given that the principles for R&D adopted in the UN Political Declaration on AMR are at the core of the framework it is of great concern to us to see “Priority Review Vouchers” and “Transferable market exclusivity” listed as possible financing mechanisms for R&D.
- These mechanisms further cement the market-based innovation model that over the last decades has failed to respond to global public health needs which has led to the decades long innovation void for the development of truly novel antibiotics.
- “More of the same” is rarely a solution to any problem – especially not one where such stark evidence exists that new approaches are needed.
- These mechanisms should therefore be marked as “not suitable” in annex 1 in the same way other mechanisms that aren’t relevant have been marked.
- The table of annex 1 should include an assessment of the degree to which these mechanisms respond to the ‘guiding principles’ listed both in the annex and under ‘3.2 Basic principles for needs-driven R&D that fosters access to new products.
- Finally, on table 1 in annex 2, on existing global, regional and industry initiatives, this only refers to initiatives on the human health side. We wonder where are the initiatives on the animal and environmental side?
More news and opinion
- Innovate4AMR: workshop for 11 finalist teams from 9 countries with WHO in Geneva
- ReAct is looking to recruit expert in antibiotic resistance to our team in Sweden
- The State of Kerala, India, launches the 1st sub-national action plan on AMR
- What’s cooking in the antibiotic pipeline?
- Latin America: One Health workshop for teachers
- Kerala, India: perspective of farmers and use of antibiotics in their aquaculture farms
- Innovate4AMR- Innovate for a world free from the fear of untreatable infections
- Definitions and strategies for continued action in Latin America
- Research project in Vietnam: results indicate very high rates of resistance to most antibiotics
- ReAct Europe keynote speaker at WFPHA side event at WHA
- ReAct Latin America: A workshop to reach commitments
- Book release in Latin America: an arena for reflection, awareness and care about antibiotics
- World health day – the rise and fall of antibiotics?
- Antibiotics in the wastewater from pharmaceutical companies: Where are we at?
- Unavailability of old antibiotics is threatening effective treatment of common bacterial infections
- New expert advisory group for the ReAct Toolbox
- ReAct is looking to recruit new Policy Advisor to our team in Sweden
- ReAct reflections on the Prince Mahidol Award Conference and the IACG Civil Society Engagement Panel
- 4 take-aways from the newly published GLASS report
- 4 needs to address so diagnostics can help contain antibiotic resistance
- ReAct responds to final report from DRIVE-AB
- WHO proposes new sepsis target to guide work and actions on antibiotic resistance
- Costing National Action Plans on AMR: practical suggestions for simplifying the process
- Joint letter to IACG on AMR: a call to increase transparency and civil society involvement